FAQ/Help |
Calendar |
Search |
Today's Posts |
![]() |
#10 | |||
|
||||
Elder
|
Quote:
The clinical trial for Tovaxin was terminated due to lack of funding. According to the research I have done, they needed less than $400,000 to finish the Phase IIb open label trial in order to move forward to the Phase III trial. Myelin Repair Foundation pulled their funding/partnership which would have allowed this drug trial to continue. No one has been able to get the attention of any other research/grant dollars to continue this so the 150 of us have been dropped. Period. We are left to find other methods to treat our MS. For a lot of us, this was a last resort. For some of us, since we were in this trial, it precludes us from eligibility for other clinical trials. Since I am a volunteer as the Government Relations Chairman for the National MS Society for Idaho, you can bet that I will be speaking to this issue at the Public Policy Conference in DC in March. This was the first drug that has worked for me and many others that were in this trial. A couple of us are writing letters to all the Legislators, the drug company, and anyone who will listen to us.
__________________
Cheryl Dx: MS 2001 CRPS 2009 “When everything seems to be going against you, remember that the airplane takes off against the wind, not with it.” - Henry Ford |
|||
![]() |
![]() |
|
|
![]() |
||||
Thread | Forum | |||
Pipeline Insight: Orphan Diseases in CNS - Part II: Amyotrophic Lateral Sclerosis | ALS News & Research | |||
Parkinson Pipeline Project...survery results | Parkinson's Disease | |||
Parkinson Pipeline Database | Parkinson's Disease | |||
Als Clinical Trials: State Of The Pipeline | ALS | |||
Safinamide in the Pipeline: triple action | Parkinson's Disease |